AKESO(HK:09926) Sou Hu Cai Jing·2025-04-22 02:05Group 1 - The Hang Seng Biotechnology Index (HSHKBIO) has seen a strong increase of 4.10%, with notable gains in constituent stocks such as Xintai Medical (02291) up 46.88%, Lepu Biopharma-B (02157) up 11.87%, and Innovent Biologics (09969) up 11.10% [1] - The Hang Seng Biotechnology ETF (513280) has risen by 2.80%, marking its third consecutive increase, with the latest price at 0.84 HKD. Over the past two weeks, the ETF has accumulated a rise of 3.27% [1] - The trading activity for the Hang Seng Biotechnology ETF has been active, with a turnover rate of 18.69% and a transaction volume of 46.885 million HKD, indicating robust market participation [1] Group 2 - The Hang Seng Biotechnology ETF has experienced a significant increase in shares, with a growth of 14 million shares over the past month, ranking it in the top third among comparable funds [3] - In terms of capital inflow, the ETF has seen net inflows on 15 out of the last 21 trading days, totaling 16.1235 million HKD [3] Group 3 - The pharmaceutical sector is showing a continuous upward recovery, with a focus on key innovative drug clinical data and milestone progress. Notable developments include the initiation of a Phase III clinical trial by Innovent Biologics for a drug targeting obstructive sleep apnea and the approval of a monoclonal antibody by CanSino Biologics [6] - The National Medical Products Administration has approved CanSino's monoclonal antibody injection for treating moderate to severe plaque psoriasis in adults [6] Group 4 - Hainan University has announced the release of its self-developed brain-computer interface (BCI) technology, marking a significant advancement in the field and enhancing China's capabilities in brain science research and medical applications [7] - The increase in tariffs on imports from the U.S. is expected to benefit domestic companies in the blood products and high-end medical device sectors, as well as in innovative drug development, promoting domestic substitutes [7] Group 5 - The Hang Seng Biotechnology ETF (513280) is noted for its low fee structure, with a management fee of only 0.15% per year, significantly lower than similar products, which could lead to better long-term returns for investors [8] - The ETF's composition includes a high proportion of innovative drugs at 66.4%, with a balanced distribution across various sectors, enhancing its investment potential [8]